Creative Biolabs is pleased to release

Creative Biolabs is pleased to release thousands of Hi-Affi™ recombinant antibodies for clinical immunotherapy research.Theses recombinant antibodies are developed with its library construction and screening processes utilizing hybridoma and phage display technology.Recombinant antibody is an antibody made through the use of recombinant DNA technologies by inserting a fragment of DNA into bacterium, yeast, and mammalian cells. Unlike traditional hybridoma based technologies, the rAbs can be expressed in an in vitro environment. The recombinant antibodies produced in an animal-free system are widely used in medical research.Recombinant antibody drugs have developed through mice monoclonal (McAb), human-mice chimeric antibody, humanized antibody and full human antibody.

They have been applied in clinical immunotherapy for the treatment of cancer, autoimmune diseases, viral diseases, Alzheimer disease and other diseases.Recombinant antibodies produced in an animal-free system are widely used in medical research as well as the preparation of pharmaceutical compounds in order to treat various diseases. However, the gap between the basic research and clinical application still need to be filled. That’s why Creative Biolabs is focusing on recombinant antibody production."Based on our optimized library construction and screening processes with hybridoma and phage display technology", said Dr. Monica Müller, scientific officer of Creative Biolabs, "we can guarantee successful isolation of clones in a short time with high affinity up to sub-nanomolar level."Recombinant antibody techniques may reduce some types of animal use but increase others. Cloned antibody genes have been used to create insect killer Suppliers transgenic mice that express murine antibodies with human constant domains (Zou et al., 1993), and more recently a complete human antibody repertoire (Jakobovits et al., 1994; Lonberg et al., 1994). Klaus Rajewsky and coworkers made a major breakthrough in this area.

They discovered how to insert an altered immunoglobulin domain transgene at the correct chromosomal location so that B lymphocytes can perform normal recombination, class switching, and affinity maturation (Taki et al., 1993). About Creative BiolabsOver the last 10 years, Creative Biolabs has becoming a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world.Our cutting-edge hybridoma development and phage display platforms allow the production of the most comprehensive list of recombinant antibody products and extensive service portfolio at the most competitive price. Our products range from antibody / peptide libraries, Biosimilar cell lines, Chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies such as therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies.